Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label
(Thomson Reuters ONE) -
Bagsværd, Denmark, 14 June 2017 - Novo Nordisk today announced the submission of
a Type II Variation application to the European Medicines Agency (EMA) for
including data in the label for Tresiba(® )(insulin degludec) from the DEVOTE
trial, a long-term, randomised, double-blinded and event-driven trial conducted
to confirm the cardiovascular safety of Tresiba(®) compared to insulin glargine
U100 when added to standard of care, in people with type 2 diabetes.
Further information
Media:
Katrine Sperling +45 4442 6718 krsp(at)novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau(at)novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak(at)novonordisk.com
Hanna Ögren +45 3079 8519 haoe(at)novonordisk.com
Anders Mikkelsen +45 3079 4461 armk(at)novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj(at)novonordisk.com
Company announcement No 44/2017
Company announcement No 44/2017:
http://hugin.info/2013/R/2113155/803847.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 14.06.2017 - 13:04 Uhr
Sprache: Deutsch
News-ID 547921
Anzahl Zeichen: 1601
contact information:
Town:
Bagsvaerd
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 166 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label"
steht unter der journalistisch-redaktionellen Verantwortung von
Novo Nordisk A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
